INTRODUCTION
LcOsc4Ccr (Lc4, lactotctraosylccramidc) is a type 1 cham carbohydrate anti gcn, which is a precursor substance for the synthcs1s of LC\\ 1s bkxxi type ant11gcns, such as Lea and Leb, and also for the synthcs1s of cancer-associated ant1igcns, such as CA 19-9 and CASO. Two murine anti-Lc4 monoclonal antibodies have been found among the antibodies raised against human teratocarcinoma cells (Gooi el a/., 1983; Rettig er at., 1985; Fukuda era/., 1986) . The disuibution of the antiigen in human embryonic tissues as well as in cancer tissues has been studied extensively using these antibodies (Gooier a/., 1983; Rettig era/., 1985; Williams et at., 1982) . The antigen is reported to be detectable in meconium and in the epithelial cells of the fetal bronchus and intestine (Williams eta/., 1982; Karlsson and Larson, 1979) . Furthermore, the antigen is expressed on the surface of a variety of human cancers including embryonal carcinoma, teratocarcinoma, renal cell carcinoma, adenocarcinoma of the gastro-intestinal tract and cancers of the uterine cervix (Rettig eta/., 1985; Williams et at., 1982; Nozawa et al.,l989; Tsukazaki era/., 1991) . In this: sense, some investigators consider Lc4 to be an onco-devclopmcntal antigen. The antiigcn is expressed in a few normal adult tissues such as some epithelial cells of the gastrointestinal tract, uterine cervical glandular cells and renal tubular cells (Rettig er a/., 1985; Williams era/. , 1982; Nozawa er a/.,1989; Tsukazaki er at., 1991 ).
An interesting aspect of the Lc4 antigen is that antibodies against this antigen have been frequently found in the sera of humans. Anti-Lc4 antibodies arc known to occur sometimes in patients with motor neuron diseases (Latov el a/., 1988; Ito and Latov, 1988) . A monoclonal paraprotein directed to Lc4 was reported to be present in the serum of a patient with lung cancer (lgMWOO) (Kabat era/., 1982) . The latter cas•~ was of particular interest, since the favorable clinical course of the patient is possibly explained by the presence of this antibody in his serum. The human m o~nocl ona l antibody directed to this antigen has not infrequently been established; in addition to IgMwoo, a human anti-LcOse4 antibody was established from the Yagoeral. PageS lymphocytes prepared from a patient with utenne endometrial cancer (Nonwa er at., 1989 ), and we also obtained a human monoclonal antibody directed to this antigen (this paper).
Recently, we and other workers ha\e examined the molecular structure of the variable regions of murine monoclonal antibodies against onco-developmental carbohydrate antigens and found restricted usage of VJ-1 and VLagamst SSE/\ I and its related antigens (Zenita er at., 1988; K11nura era/., 1989; Snyder eta!., 1990) . A si milar finding is also reported with regard to human anti-carbohydrate antibodies; the anti-I antibodies which accumulate in the sera of patients with cold agglutinin disease were recently shown to be encoded by a highly homologous series of VH genes (Leoni el a!., 1991; Pascual eta!., 1991 ) . We report here the nucleic and derived amino acid sequences of the immunoglobulin variable regions of the two human monoclonal antibodies recognizing LC4.
MATERIALS AND METHODS

Generation of hybridoma cells
The heterohyb1icloma 11-50 (IgM, A.) was obtained according to the method described by Kohler and Milstein (1975) . BrieOy, human lymphocytes isolated from a surgically resected tonsil were fused with hypoxanthine-aminopterin-thymidinesensitive murine fusion partner cells (P3/X63-Ag8Ul) at a ratio of 2:1 using polyethylene glycol. The glycolipid mixture prepared from /\.375 cells was used as the anti gen in ELISA of culture supernatants of hybridomas 111 the cloning procedures. I !eterohybridoma HMST-1 (lgM, A.) was obtained as previously described (No?.awa eta/., 1989) .
G3, an anti-idiotypic antibody against 11-.50, was established according to the previously described methods (Hirashima eta/., 1990) . BALB/c mice were immunized at day 0, day 7 and day 28, with 100 J.tg of the 11-50 antibody which was Yago et al. Page 6 conjugated with KLH. The spleen cells were fused with mouse myeloma cells P3/X63-Ag8U I (P3U I) on day 31. The antibody 11-50 was used as the irnmobih7ed antigen in ELISA of culture supernatants of hybridomas for the cloning procedures.
The isotypc of the 03 antibody was lgO 1, K. To test the inhibitory activity of 03 to the binding of 11-50 with the original antigen, Lc4 was immobilized at the bottom of the wells of the 96-well plate. To this, 03 and biotinylated 11-50 were added, followed by the addition of avtdin-peroxidase (2~t g/ml) and substrate solution (0-phenylenediami ne).
Cultured Cells and Preparation of Standard Glycolipids.
I Iuman melanoma cells (A375), teratocarcinoma cells (2102Ep), colon carcinoma cells (LS l74T, SW80, SW48, I lT29, BM314), breast cancer cells (T470) and lung cancer cells (KNS62) were cultured in Dulbccco's modified MEM supplemented with 10% fetal calf serum. For the preparation of glycolipids from these~ cells, tumors xenografted to nude mice were used as starting material.
Olycolipids were prepared from these tumor tissues by the method described earlier (Hakomori and Kannagi, 1986) . Brieny, total lipids were extracted from those tissUJes with isopropanol/ hexane/ water (55:20:25, v/v/v) and partitioned according to Folch. The glycolipids in the lower layer fraction of the Folch partition were further puri f ied by acetylation followed by Aorisil column chromatography, and subjected to DEAE-Sephadex /\-25 (Pharmaeia, Uppsaln, Sweden) column chromatography. The neutral glycolipids were eluted with chloroform/ methanol/ water (30:60:8, v/v/v, fraction A) and gangliosides, were then eluted with chloroform/ methanol/ 0.8N sodium acetate (30:60:8, v/v/v, fraction 8) . In some experiments, neutral glycoliptds in the fraction 1\ were further separated by preparative TLC using the solvent system; chlowform/ methanol/ water (60:35:8, v/v/v) . Pure Lc4 was prepared by defucosylation of Lea which was prepared from the neutral glycolipid fraction of either human meconium or cultured colon cancer cells (Karlsson and Larson, I 979; I wamori eta!., 1988) . OM 1, 0M2 and 0M3 were purchased from Supclco Inc. (Bellfonte, PA). Astalo·GMl (Gg4) and astalo-GM2 (Gg3) were prepared by mild acid hydrolysis of OM 1 and 0M2 gangliOS!des, respectively (Taki et al., 1984; Shigeta et al., 1987) . SSEA-3 (IV3Gai0Gb4) was purilfied from human teratocarcinoma cell line, 2102Ep, as described previOusly (Kannagi et al., l983a; Kannagi et al., 1983b) . Paragloboside (nLc4) was prepared by preparative TLC of acidic glycolipid fracl!ons of human erythroc) tes '' h1ch had been mildly acid-hydroly7.ed. Amino-CTH (l_.c3) was prepared by hydrolysiS of paragloboside using Jack bean p-galactosidase (Sigma, St. Louis, MO). The IV2Fuca.nLc4 (I 11 -glycolipid) and JV3Gal0nlc4 (Kraus-glycolipid) were purified from the same source as described earlier (Hakomori eta/., 1986) .
Assessment of the specificity of mAbs toward various glycolipids
TLC-immunostaining was performed using a IIPTLC plate (Si-1 IPP plate 7011-3, J. I. Baker Chemical Co., Phillipsburg, NJ) and l25J-protein A (Dupont, Boslon, MA) as described first by Magnani et al. ( 1980) and subsequently modified by us (Kannagi eta/., 1982) . ELISA was performed using glycolipid antigens immobilized at the bottom of 96-well plates by a standard method described previously (Hakomori et al., 1986) . Peroxidase-conjugated goat anti -human lgM (~t chain specific) and anti-human IgG (y-chain specific) antibodies were obtained from Cappel Inc. (Malvern, PA).
Detection of idiotype positive component in pooled normal human sera
Pooled normal human sera were applied to a Synsorb affinity column on which Gal~ l-+3GlcNJ\cf3 is immobilized (Chembiomed LTD, Alberta, Canada).
I Iuman pooled sera which had been x 5 diluted with PBS were subjected to the column. After extensive washing with 0.1 M NaHC03, 0.5 M NaCl, the adsorbed antibodies were eluted with 0.2 M glycine-HCI, pi I 2.3. The eluates were neutralized with 1.0 M Tris-HCI, pH 8.5, and the titer of the 11-50-like antibody in each fraction was measured by ELISA using a combination of the immobilized neutral glycolipids fronTl LS174T cells which contains Lc4 and the b1otmylated anti-id10typic ant1lxxl) 03. First, the neutral glycolipids of LSJ74Tcells was Immobilized at the lxHtom of each wel l of the 96 well plates, and, after blocking, they were reacted w1th fractionated human senun samples. To this, the biotinylated 03 antibody, avidinperoxidase, and substrate solution were added sequentially. The titc1 of the 03-idiotype-positivc anti-I...c4 antibody \\'US measured in this assayS) stem. One unit is dc:fined as absorbance at 500 nm when ll -50 (l~tg/ml) was assayed.
Sequencing of immunoglobulin heavy and light chain variable region genes
Total RNA was prepared from 1 x loS cells using the guanidine isothiocyanate method. Poly (A)+ RNA ''as isolated using Oligotex dT30 (Takara Inc., Kyoto, Japan). Direct sequencing of mRNA of immunoglobulin heavy and light chain variable region genes was perfonned using the didcoxy chain tem1ination method (Ocliebter et at., 1986). The 5'-end of the primers was labeled with 32p, The mixture of the primer and mRNA was heated at l00°C for 2 min and cooled to room temperature for 30 min. Avian myeloblastosis virus reverse transeriptase (Life Sciences, StPetersburg, FL), deoxy-and dideoxy-NTPs (Takara Inc., Kyoto, Japan) were added to the annealing mixture, and incubated at 48°C for 60 m1n. The eDNA fragments were separated by electrophoresis using 6% or 8% polyacrylamide urea gels,. and detected by autoradiography. Partial sequences of variable regions were obtained using the universal oligonucleotide primers, which were 5'ACOCTOCT COTATCCOAC3' for the C~t gene and 5'CAOTOTOOCCTIOTIOOCTT03' for the CA gene. Primers for further extension were synthesized according to the obtained parti al seq uence data; 5'COTOTTCTTOOAA TTOTC3' for the VH gene and 5'AGOCCOTOTTOCCAOACTI3' for the VA gene. Sequencing \vas performed as described above and the total sequences of the coding regions were obtained.
In order to confirm the V region sequences obta1ned by mRNA sequenemg, RT-IPCR was pcrfonned to amplify the rca1rangcd immunoglobulin variable regions. 
RESULTS
Carbohydrate specificities of the human anti-l..£4 antibodies I 1 50 and JIMST-1
In our preliminary experiments, se,eral cultured human cancer cell lines, including melanoma cells (A375), colon cancer cells (LS 174T, SW80, SW48, HT29, BM3 14), breast cancer cells (T47D) and lung cancer cells (KNS62) were found to express the antigen which was recognized by the 11-50 anttbody.
When the neutral glycolipids extracted from LSI74T cells were tested for reactivity with the ll-50 antibody by TLC-irnmunostaining technique, a clear posi tive band was identified as shown in Fig. I , Lane 2. The LS 174T cells contained a large amount of the reactive glycolipid. Comparing the TLC mobilities of various glycolipids as seen in the orcmoi/H2S04 statnmg (Fig. l. Lane 1) , the reacllvc glycolipid was thought to be a glycolipid havmg 3 to 5 sugar residues. The TLC mobility of the reactive glycolipid was identical to the mobi lity of the glycolipid band detected with the I IMST -1 antibody (Fig. I, Lane 3) , which is reported to be reactive with Lc4.
ELISA using a panel of various standard glycolipids was pet fonned, to determine whether the glycolipid rccogni7ed by 11 -50 is Lc4. The ll -50 anttbody strongly reacted with Lc4 having Gal~ 1 ~3GicNAcf3 tetminus (Fig. 2) . It also reacted weakly with asialo-G MJ (Gg4) and SSEA-3 (IV3Gai~Gb4), both of which have the Galf3J ~3GaiNAcB terminus. No reactivity was observed with nLc4 (paragloboside, having the Galf31 ~4Glc N A cf3 terminus), asialo-GM2 (Gg3, havmg the GaiNAcf31 ~4Galf3 terminus), amino-CTH (Lc3, havi ng the GlcNJ\cf31 ~3Gal~ lenni nus), 0M3 (having the NeuAco2~3Galf3 terminus), IV2FucanLc4 (I I! -glycolipid) or I v3oaiBnLc4 (Kraus-glycolipid). These results indicate that the carbohydrate structure recognized by 11-50 is Lc4 having the Gal~1 ~3GlcN J\cf3 terminus, and the antibody is slightly cross-reactive with other glycolipids havmg the Gal~l ~3GalNAcf3 terminus. The result of TLC-immunostaining using these purified glycolipid standards also confirmed that Lc4 was the only reactive glycolipid (data not shown). The pure Lc4 antigen oligosaccharide (lactotetraose) completely inhibit the reacti on of 11 -50 antibody with J\375 and LS174T cells at the conoentration of 7.2 x w-4 M, which also confirmed that Lc4 is the cell surface antigen recognized by the 11-50 antibody. 
Detection of idiotype positive component in pooled normallwman sera
The anti-ld antibody 03, raised agamst the 11-50 anttbody had a strong binding activity to the 11-50 antibody, and had no rcacttvtty against four other control human monoclonal antibodies (all IgM, including three IgM, K and one lgM, A.). The 03 antibody did not react even \\'ith IIMST-1, and \\US tcntattvcly assumed to be specific to a private idiotopc carried by 11-50. The 03 antibody had a strong inhibitory activity towards the binding of the 11-50 antibody wi th the Lc4 antigen, indicatin g that this anti-ld antibody reacts with the antigen binding site of the 11-50 anti l body; i.e., the 03 antibody is a paratopc related anti-ld antibody (Fig. 4) .
::.; 'j · ~l
When the reactivity of the 03 antibody towards the ll-50 antibody was analyzed by Western blotting technique, the results indicated that it recognized the idiotope which was formed by both heavy and light chains of the L 1-50 antibody, and that it was not reactive with separated heavy or light chains of the antibody (data not ::;hown).
When human polyclonal anti-Lc4 antibodies were purified from pooled human sera by Lc4-affinity chromatography, essentially all of the anti-Lc4 antibodies were recovered in the adsorbed fraction, when tested by ELISA using the immobili zed Lc4 antigen. The purified human polyclonal anti-Lc4 antibodies were then tested for the reactivity with the 03 antibody as well as the reactivity with the Lc4 antigen in a sandwich assay system using immobilized neutral glycolipids from LS174T cells and the biotinylated 03 antibody. As shown in foig. 5, significant f 1 d ~ reactive materials were detected only in the adsorbed fraction and not in the passthrough fraction. These reactive materials turned out to be mostly IgM accompanied by a small amount of IgG, when ascertained with goat anti-human p,-andy-chain specific antibodies. These results indicate that the 03 idiotopc is not a private idiotopc, but is a shared crossrcactive idiotopc, and that the pooled normal human sera contain a certain amount of the anti-Lc4 antibody which shares the 03-tdiotopc with 11-50. Ji-l segments of both antibodies were encoded by JI J4.
The VA. segments of these two antibodies also had a high homology (96.3% at the nucleic acid level), and were encoded by the VA. gene members \\'h1ch belong to the VA.II family (Fig. 7) . The absence of sufficient gcrmline sequence data in data banks made it impossible to determine the exact gcrmline counterparts of these VA.
segments. Among the rearranged VA. genes ever reported, VA.! I. OS (Paul eta f., 19911) had the highest homology to the VA. segments of 11-50 and HMST-1. The VA.
segments of both 11-50 and I IMST-1 arc 96.6% homologous to VA.II.DS at the nucleic acid lc,·cl. At the amino acid level, they were 92.7% and 94.5% homologous to VA.II.DS, respectively. The JA. segments of 11 -50 and HMST-1 were encoded by JA2 and JA.3, and amino acid sequence of the JA. segments of the two antibodies were idcnrtical.
A few somati c mutations seemed to occur sporadically both 111 the heavy and light chain ,·ariablc regions of these antibodies. These somatic mutations were observed both in the framework regions (rR) and the complementanty-detenniningrcgions (CDR).
DISCUSSION
The Lc4 antigen is known to be frequently expressed in various human cancer cells. In this paper we established the human monoclonal antibody II 50 directed to Lc.4, and the murine monoclonal anti-idiotyptc antilxx.ly, G3, directed to an tdtotypc carried by the I 1-50 anttbody. The G3 idtoty pc was shown to be shared by at least a part of human polyclonal anti-Lc4 antibodtes in pooled human sera.
At least some of the antibodies directed to carbohydrate antigens arc known to be oligoclonal and to have a high idiotypic connectivity. For example, in the murine sys:tem, anti-idiotypic antibodies raised against antibodies toward oncodcvclopmental carbohydrate antigen SSEA-1 (LeX) and related antigens react with other antibodies recognizing original antigens (Hirashima eta/., 1990; Umcda eta!., 1986) . Approximately 50% of the murine anti-SSEA-1 (anti-LeX) antibodies share the 681 idiotypc (Umcda eta!., 1986) and about 66% of the anti-fucosyl SSEA-1 (anti-LeY) antibodies carry the common 84 idiotype (Hirashima et at., 1990) . In humans, it had already been shown as early as in 1968 that most of the human antibodies directed to both 1-and i-antigcns carry common cross-reactive idiotypcs (Williams et at., 1968) , and more recently, human antibodies against capsular pol ysaccharidc of Jiaemophilus i njluenzae were shown to share cross reactive idiotypcs (Lucas, 1988) .
Regarding the molecular basis of idiotypic connectivity of antibodies, tt is considered that antibodies arc encoded by the same or closely related immunoglobulin variable region genes (Pascual et al., 1991; Chen et al., 1985) . As to the murine monoclonal antibodies against onco-dcvelopmental cat bohydratc antigens, the variable regions of most anti-SSEA-1 (anti-LeX) and anti SSEA-3 monoclonal antibodies are known to be encoded by VH441 (Zenita eta!., 1988; Kimura eta/., 1989; Snyder et al., 1990) . The variable regions of most antt-fucosyl SSEA-1 (anti-LeY) antibodies arc coded by VHSO.l and VKKl AS (Zcnita el a/., manuscript in preparation). The idiotypic connectivity of human anti-Lc4 antibodies suggests that these anttbod1cs arc encoded also b) a rcstnctcd set of vanablc rcg1on genes, and that the 03 antibody recogni1cs the idJOt) pc '' h1ch is closely associated with these particular genes.
We tried to examine if the usage of the variable regions of human monoclonal antibodies against onco-devclopmental anllgens arc restricted, as 111 the case of murine antibodies (Zcnita el a!., 1988; Kimura el al., 1989; Snyder el a!., 1990) 
1989; Zcnita el al. manuscript in preparation)
. Surprisingly, in spite of the homology of the va~iablc regions of 11-50 and HMST-1, the anti-idiotypic antibody 03 reacted only with 11-50 and the anti-Lq antibodies detected in pooled normal human sera, not with HMST-l. This lack of crossreactive 03 1diotype shared by ll-50 and polyclonal anti -Lq antibodies of HMST-1 may be under the innucnce of the differences of the CDR 3 region of the heavy chain from that of 11-50, or due to the somatic mutations in other regions. Since 03 recognizes the idiotope formed by both heavy and light chains, as previously described, and it reacted also with polyclonal anti-Lc4 antibodies, it is not considered that 03 idiotypc is located solely in the VH CDR3 region ofll-50. Considering the fact that ll-50 is dc1ived from lymphocytes from a tonsil of a patient with non-malignant disease, and I IMST-l from regional lymph node cells of a cancer patient, it is interesting to speculate that I IMST-l lost the cross-reactive 03 idiotype of anti-Lc4 natural antibodies through the somatic mutations acquired during the course of the disease. The exact amino acid differences that can explain the difference of the reactivities agamst the antiidiotypic antibody is ctmently unknown, but site-directed mutagenesis study can help to solve the problem.
The VII regions of 11 -50 and HMST I arc highly homologous to Vul.9111 and l hv3005f3 gcrmlinc genes, respectively. VI II.91Il and hv3005f3 arc members of the c:loscly related VHIII gcrmlinc genes aml 98.6% homologous at the nuclctc acid level (Olcc eta!., 1991) . An important pomt to note is that some members of VI {Ill segments arc preferentially utili?.cd in the human fetal repertoire, and that rc::mangcd immunoglobulin heavy chain genes FL2-2 and M72 which ha\'C been isolated from fetal liver ate encoded by VH 1.9111 and ll\ 3005f3 genes\\ ith only one or wrthout any mutation, respectively (Schroeder et at., 1987; Nickerson et at., 1989; Schroeder and Wang, 1990) . It is known that some members of the immunoglobulin variable genes arc selectively rcaJTangcd in fetal 8 cells (Pcrl multcr eta/., 1985; Yancopoulos eta!., 1988) . The VJ JI.91JI and hv3005f3 genes arc most probably examples of such genes which arc preferentially rcatTangcd in fetal B cells. Besides, they arc also used by natural autoantibodies (Siminovitch and Chen, 1990) .
It is reported from the studies using murine anti-Lc4 antibodies that the Lc4 antig;cn is strongly expressed in the embryonic and fetal periods (Rettig et at., 1985; Will: iams eta/., 1982; Karlsson and Larson, 1979) In the sterile fetal environment, immature B cells would not be frequently sttmu lated by exogenous antigens, but the cmbtryonic carbohydrate antigens including Lq as well as other autoantigcns may stim1ulate·a subset of primitive B cells expressing a preferentially-rearranged immunoglobulin variable region genes. This subset of 8 cells could be the producers of SUich natural autoantibodtcs. It would be interesting to speculate that a similar B cell subset would be stimulated and produce anti-Lc4 antibodies when the LC4 is expressed on cancer cells in adults, as in the case of IgM'voo (Kabat et al., 1982) . In the case of IgM"'OO, a patient with bronchogenic carcinoma, who showed an unusually favorable clinical course, was rcpottcd to have a monoclonal anti-Lc4 antibody in his serum, and the antibody was suggested to be involved in the immune reaction towards the cancer cells.
With regard to the light chains, all three human antt-Lc4 antibodies known to date have A.-light chains. We clarified here that VA. of 11-50 and I !MST-1 arc encoded by the same 01 closely related gcncc;. /\ga1n they show vcr) high homology to a rearranged VA. gene VAJ I.DS which \\'as util i1cd 111 autoantibody associated w1th lupus erythematosus. Whether the gcnnlinc gene for VA.II.DS is preferentially used in the fetal repertoire is currently unknown.
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